Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Karin M. Knudson, Kristin C. Hicks, Yohei Ozawa, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000493-e000493
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Managing the TME to improve the efficacy of cancer therapy
Maria Teresa Bilotta, Antonella Antignani, David Fitzgerald
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 133
Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy
Shoubao Ma, Michael A. Caligiuri, Jianhua Yu
Trends in Immunology (2022) Vol. 43, Iss. 10, pp. 833-847
Open Access | Times Cited: 108
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 2, pp. 192-209
Open Access | Times Cited: 102
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine Huang, et al.
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114112-114112
Open Access | Times Cited: 96
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Ivan S. Pires, Paula T. Hammond, Darrell J. Irvine
Advanced Therapeutics (2021) Vol. 4, Iss. 8
Open Access | Times Cited: 74
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Christine M. Minnar, Paul L. Chariou, Lucas A. Horn, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004561-e004561
Open Access | Times Cited: 32
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy
Zhenhua Ren, Xuhao Zhang, Yang‐Xin Fu
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2025-2038
Closed Access | Times Cited: 7
IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside
Sogand Vahidi, Arefeh Zabeti Touchaei, Ali Akbar Samadani
International Immunopharmacology (2024) Vol. 133, pp. 112156-112156
Closed Access | Times Cited: 7
Biological effects of IL-15 on immune cells and its potential for the treatment of cancer
Shuling Zhang, Jianzhu Zhao, Xueli Bai, et al.
International Immunopharmacology (2020) Vol. 91, pp. 107318-107318
Closed Access | Times Cited: 48
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
Jiao Shen, Zhuangzhi Zou, Jingya Guo, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 12
Open Access | Times Cited: 23
Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC
Vasiliki Stravokefalou, Dimitris Stellas, Sevasti Karaliota, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 14
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ruiyang Ren, Chenyi Xiong, R.C-S. Ma, et al.
MedComm (2023) Vol. 4, Iss. 4
Open Access | Times Cited: 14
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy
Lei Wang, Qingzhu Jia, Qian Chu, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2023) Vol. 1, Iss. 1, pp. 18-29
Open Access | Times Cited: 11
Immune evasion and therapeutic opportunities based on natural killer cells.
Jinjin Zhang, Feifei Guo, Lingyu Li, et al.
PubMed (2023) Vol. 35, Iss. 3, pp. 283-298
Closed Access | Times Cited: 11
Engineering cytokines for tumor-targeting and selective T cell activation
Kun Peng, Yang‐Xin Fu, Yong Liang
Trends in Molecular Medicine (2025)
Closed Access
Cancer immunity by tissue‐resident type 1 innate lymphoid cells and killer innate‐like T cells
Jing Zhang, Albert M. Li, Emily R. Kansler, et al.
Immunological Reviews (2024) Vol. 323, Iss. 1, pp. 150-163
Closed Access | Times Cited: 3
Advancements and challenges in immunocytokines: A new arsenal against cancer
Wenqiang Shi, Nan Liu, Huili Lu
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 11, pp. 4649-4664
Open Access | Times Cited: 3
Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy
Alexandra A. Wolfarth, Swati Dhar, Jack B. Goon, et al.
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapy
Juntao Yu, Qian Li, Shenggen Luo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions
Juntao Ran, Jiangtao Wang, Ziying Dai, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 14
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
Jiacheng Huang, Lele Zhang, Jianxiang Chen, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 14
Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment
Veronica Veschi, Alice Turdo, Giorgio Stassi
Frontiers in Molecular Medicine (2023) Vol. 3
Open Access | Times Cited: 4
In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells
Robin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Immunotherapy induced by plant microRNA via ionizable Lipid Nanoparticles delivery enhances chemotherapy effects of Triple-negative breast cancer
Hanyi Ye, Yifan Feng, Ze Wu, et al.
Research Square (Research Square) (2024)
Open Access
Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer
Anusha Gupta, Shiv Verma, Sanjay Gupta
annals of urologic oncology (2024)
Open Access
Page 1 - Next Page

Scroll to top